Developing U.S. oversight strategies for nanobiotechnology: Learning from past oversight experiences

Journal of Law, Medicine and Ethics

Volumn 37, Issue 4, 2009, Pages 688-705

  Paradise, Jordan ^a   Wolf, Susan M ^b   Kuzma, Jennifer ^b   Kuzhabekova, Aliya ^b   Tisdale, Alison W ^b   Kokkoli, Efrosini ^b   Ramachandran, Gurumurthy ^c  

^a SETON HALL UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c University of Minnesota's School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; BIOTECHNOLOGY; COMPARATIVE STUDY; CONFERENCE PAPER; CONSENSUS; DECISION SUPPORT SYSTEM; GOVERNMENT REGULATION; HEALTH SERVICES RESEARCH; HUMAN; INTERDISCIPLINARY COMMUNICATION; LEGAL ASPECT; LITERATURE; MANAGEMENT; NANOTECHNOLOGY; SYSTEM ANALYSIS; UNITED STATES;

BIOTECHNOLOGY; CONSENSUS; DECISION SUPPORT TECHNIQUES; GOVERNMENT REGULATION; HUMANS; INTERDISCIPLINARY COMMUNICATION; NANOTECHNOLOGY; ORGANIZATIONAL CASE STUDIES; POLICY MAKING; REVIEW LITERATURE AS TOPIC; SYSTEMS ANALYSIS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 76149098834     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/j.1748-720X.2009.00441.x     Document Type: Conference Paper

References (79)

1. See J. Abraham, "Regulatory Science as Culture: Contested Two-Dimensional Values at the US FDA Science as Culture 11, no. 3 (2002 309 335.
2. J. B. Wiener, "The Regulation of Technology, and the Technology of Regulation Technology in Society 26, nos. 2-3 (2004 483 500, at 489.
3. See generally Id. (tracing the development and effects of various types of regulatory instruments).
4. M. C. Roco, "Nanotechnology: Convergence with Modern Biology and Medicine Current Opinion in Biotechnology 14, no. 3 (2003 337 346, at 337.
5. For purposes of analysis, oversight of drugs and medical devices was analyzed in a single article due to commonalities between the two oversight systems at the U.S. Food and Drug Administration. Throughout this comparative article, we will refer to that single article as containing two case studies. Thus, there are a total of five case studies (oversight of GEOs, drugs, devices, workplace chemicals, and gene therapy).
6. See J. Kuzma, P. Najmaie, and J. Larson, "Evaluating Oversight Systems for Emerging Technologies: A Case Study of Genetically Engineered Organisms Journal of Law, Medicine & Ethics 37, no. 4 (2009 546 586)
7. J. Paradise et al., "Evaluating Oversight of Human Drugs and Medical Devices: A Case Study of the FDA and Implications for Nanobiotechnology," Journal of Law, Medicine & Ethics 37, no. 4 (2009): 598-624
8. J. Young Choi and G. Ramachandran, "Review of the OSHA Framework for Oversight of Occupational Environments," Journal of Law, Medicine & Ethics 37, no. 4 (2009): 633-650
9. S. M. Wolf, R. Gupta, and P. Kohlhepp, "Gene Therapy Oversight: Lessons for Nanobiotechnology," Journal of Law, Medicine & Ethics 37, no. 4 (2009): 659-684.
10. Woodrow Wilson International Center, Project on Emerging Technologies, "Nanotechnology Consumer Products Inventory available at http://www.nanotechproject.org/inventories/consumer/ last visited September 18, 2009).
11. K. E. Drexler, "Molecular Engineering: An Approach to the Development of General Capabilities for Molecular Manipulation Proceedings of the National Academy of Sciences 78, no. 9 (1981 5275 5278.
12. G. Binnig and H. Rohrer, "Scanning Tunneling Microscopy IBM Journal of Research and Development 30, no. 4 (1986 355 369.
13. H. W. Kroto et al., "C60: Buckminsterfullerene Nature 318, no. 6042 (1985 162 163.
14. R. W. J. Scott, O. M. Wilson, and R. M. Crooks, "Synthesis, Characterization, and Applications of Dendrimer-Encapsulated Nanoparticles Journal of Physical Chemistry B 109, no. 2 (2005 692 704.
15. Id.
16. M. Bruchez Jr. et al., "Semiconductor Nanocrystals as Fluorescent Biological Labels Science 281, no. 5385 (1998 2013 2016.
17. V. Balzani et al., "Designing Dendrimers Based on Transition-Metal Complexes: Light Harvesting Properties and Predetermined Redox Patterns Accounts of Chemical Research 31, no.1 (1998 26 34.
18. R. H. Baughman, A. A. Zakhidov, and W. A. de Heer, "Carbon Nanotubes: The Route Toward Applications Science 297, no. 5582 (2002 787 792 Y. Xia et al., "One Dimensional Nano-structures: Synthesis, Characterization, and Applications," Advanced Materials 15, no. 5 (2003): 353-389.
19. T. O. Pangburn et al., "Peptide and Aptamer Functionalized Nanovectors for Targeted Delivery of Therapeutics Journal of Biomechanical Engineering 131, no. 7 (2009 074005-1-074005-20)
20. A. Garg et al., "Targeting Colon Cancer Cells Using PEGylated Liposomes Modified with a Fibronectin-Mimetic Peptide," International Journal of Pharmaceutics 366, no. 1-2 (2009): 201-210
21. D. Demirgöz, A. Garg, and E. Kokkoli, "PR-b-targeted PEGylated Liposomes for Prostate Cancer Therapy," Langmuir 24, no. 23 (2008): 13518-13524.
22. See Pangburn et al., supra note 16.
23. Environmental Protection Agency, Nanoscale Materials Stewardship Program Interim Report, available at http://www.epa.gov/oppt/nano/nmsp-interim-report- final.pdf last visited September 18, 2009).
24. Environmental Protection Agency, "Toxic Substances Control Act Inventory Status of Carbon Nanotubes Federal Register 73 (October 31, 2008 64946.
25. H.R. 554, 111th Congress (2009).
26. California Department of Toxic Substances Control, "Chemical Information Call-in: Carbon Nanotubes available at http://www.dtsc.ca.gov/ TechnologyDevelopment/Nanotechnology/index.cfm last visited September 18, 2009).
27. Berkeley Municipal Code, §15.12.040-15.12.050 (2006).
28. United Kingdom, Department for Environmental Food and Rural Affairs, Voluntary Reporting Scheme for Engineering Nanoscale Materials (London : Crown, 2008 available at http://www.defra.gov.uk/environment/nanotech/policy/pdf/vrs- nanoscale.pdf last visited February 24, 2009).
29. United Kingdom Royal Society, Nanoscience and Nanotechnologies: Opportunities and Uncertainties, London, 2004, at 85, available at http://www.nanotec.org.uk/finalReport.htm last visited September 18, 2009).
30. V. Gill, "Nanotechnology Regulation Creeps Closer Chemistry World, February 25, 2009, available at http://www.rsc.org/chemistryworld/News/2009/ February/25020901.asp last visited September 18, 2009).
31. K. Ludlow, D. Bowman, and G. Hodge, "A Review of Possible Impacts of Nanotechnology on Australia's Regulatory Framework September 2007, available at http://nano.foe.org.au/filestore2/download/248/Review%20of%20Nano- technology%20Regulation%20in%20Australia%20-%20Monash%20Report%20July%202008. pdf last visited November 6, 2009).
32. European Commission, Communication from the Commission to the Council, the European Parliament and the Economic and Social Committee, Nanosciences and Nanotechnologies: An Action Plan for Europe 2005-2009, Luxemburg, 2005, available at http://eescopinions.eesc.europa.eu/viewdoc.aspx?doc= %5C%5Cesppubl%5Cesp-public%5Cces%5Cint%5Cint277%5Cen%5Cces582-2006-ac-en.doc last visited September 18, 2009).
33. See, e.g., W. B. Schultz and L. Barclay, A Hard Pill to Swallow: Barriers to Effective FDA Regulation of Nanotechnology-Based Dietary Supplements, Project on Emerging Technologies, Washington, D.C., 2009
34. S. N. Luoma, Silver Nanotechnologies and the Environment, Project on Emerging Technologies, Washington, D.C., 2008
35. E. M. Felcher, The Consumer Product Safety Commission and Nanotechnology, Project on Emerging Technologies, Washington, D.C., 2008
36. J. C. Davies, Nanotechnology Oversight: An Agenda for the Next Administration, Project on Emerging Technologies, Washington, D.C., 2008
37. J. Paradise et al., "Developing Oversight Frameworks for Nanobiotechnology," Minnesota Journal of Law, Science & Technology 9, no.1 (2008): 187-203
38. M. C. Roco, "Possibilities for Global Governance of Converging Technologies," Journal of Nanoparticle Research 10, no. 1 (2008): 11-29
39. M. R. Taylor, Assuring the Safety of Nanomaterials in Food Packaging: The Regulatory Process and Key Issues, Project on Emerging Technologies, Washington, D.C., 2008
40. L. K. Breggin and J. Pender-grass, Where Does the Nano Go? End-of-Life Regulation of Nanotechnologies, Project on Emerging Technologies, Washington, D.C., 2007
41. J. C. Davies, EPA and Nanotechnology: Oversight for the 21st Century, Project on Emerging Technologies, Washington, D.C., 2008
42. J. Kuzma, "Moving Forward Responsibly: Oversight for the Nanotechnology-Biology Interface," Journal of Nanoparticle Research 9, no. 1 (2007): 165-182
43. M. Greenwood, Thinking Big about Things Small: Creating an Effective Oversight System for Nanotechnology, Project on Emerging Technologies, Washington, D.C., 2007
44. M. R. Taylor, Regulating the Products of Nanotechnology: Does FDA Have the Tools It Needs? Project on Emerging Technologies, Washington, D.C., 2006
45. J. C. Davies, Managing the Effects of Nanotechnology, Project on Emerging Technologies, Washington, D.C., 2006
46. K. W. Abbott, G. E. Marchant, and D. J. Sylvester, "A Framework Convention for Nanotechnology?" Environmental Law Reporter 36, no. 12 (2006): 10931-10942; J. Kuzma, ed., University of Minnesota Center for Science, Technology and Public Policy Workshop Report, The Nanotechnology-Biology Interface: Exploring Models for Oversight, September 15, 2005, available at http://www.hhh.umn.edu/centers/stpp/pdf/nanotech-bio-interface.pdf last visited September 18, 2009); American Bar Association, "Section of Environment, Energy, and Resources: Nanotechnology Project," available at http://www.abanet.org/environ/nanotech/ last visited September 18, 2009); International Center for Technology Assessment, Principles for the Oversight of Nanotechnologies and Nanomaterials, July 31, 2007, available at http://www.icta.org/doc/ Principles%20for%20the%20Oversight%20of%20Nanotechnologies%20and%20Nanomaterial s-final.pdf last visited September 18, 2009); U.S. Environmental Protection Agency, Science Policy Council, Nanotechnology White Paper, Washington, D.C., 2007, available at http://es.epa.gov/ncer/nano/publications/whitepaper12022005. pdf last visited September 18, 2009); U.S. Food and Drug Administration, Nanotechnology Task Force, Nanotechnology: A Report of the U.S. Food and Drug Administration, July 25, 2007, available at http://www.fda.gov/nanotechnology/ taskforce/report2007.pdf last visited September 18, 2009); National Nanotechnology Initiative, National Science & Technology Council, Environmental, Health, and Safety Research Needs for Engineered Nanoscale Materials, National Nanotechnology Coordination Office, Washington, D.C., 2006, available at http://www.nano.gov/NNI-EHS-research-needs.pdf last visited September 18, 2009); National Research Council, Review of Federal Strategy for Nanotechnology-Related Environmental, Health, and Safety Research (Washington, D.C.: National Academies Press, 2008), available at http://www.nap.edu/catalog. php?record-id=12559 last visited September 18, 2009).
47. National Academy of Sciences, Committee on the Introduction of Genetically Engineered Organisms into the Environment, Introduction of Recombinant-DNA Organisms into the Environment (Washington, D.C. : National Academies Press, 1987).
48. Office of Science and Technology Policy, Coordinated Framework for the Regulation of Biotechnology, 51 Federal Register § 23302 (1986).
49. J. Kuzma and P. Verhage, Nanotechnology in Agriculture and Food Protection, Project on Emerging Technologies, Washington, D.C., 2006.
50. Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. §§ 351-360 (2008).
51. J. Paradise et al., "Exploring Emerging Nanotechnology Drugs and Medical Devices Food and Drug Law Journal 36, no. 2 (2008 407 420, at 411-414.
52. See FFDCA, supra note 32.
53. See Paradise et al., supra note 33, at 415-417.
54. G. E. Ziem and B. I. Castleman, "Threshold Limit Values: Historical Perspective and Current Practice Journal of Occupational Medicine 31, no. 11 (1989 910 918.
55. Mine Safety and Health Act, 30 U.S.C. §§ 801-965 (2008).
56. Occupational Safety and Health Act, 29 U.S.C. §§ 651-678 (2008).
57. Toxic Substances Control Act, Subchapter I: Control of Toxic Substances, 15 U.S.C. §§ 2601-2629 (2008).
58. See Wolf, Gupta, and Kohlhepp, supra note 6.
59. Food and Drug Administration, Center for Devices and Radiological Health Strategic Plan, Total Product Life Cycle Model, available at http://www.fda.gov/cdrh/strategic/tplc.html last visited November 4, 2009).
60. See references to all case studies in this symposium, supra note 6.
61. The exact survey instrument and methodology employed for expert elicitation varied somewhat among the case studies, given the different subject matter. For specific information, refer to each case study in the symposium.
62. See J. Kuzma et al., "An Integrated Approach to Oversight Assessment for Emerging Technologies Risk Analysis 28, no. 4 (2008 1197 1219.
63. See references to all case studies in this symposium, supra note 6.
64. Note that the case study on chemicals in the workplace used 26 criteria, not 28, as two of the oversight evaluation criteria were not germane.
65. For additional information and explanation, refer to the case studies in this symposium on drugs and medical devices, GEOs, and workplace chemicals, see supra note 6.
66. See, e.g., G. Morgan and M. Henrion, Performing Probability Assessment in Uncertainty (Cambridge, U.K. : Cambridge University Press, 1990 at 141-171.
67. See references to all case studies in this symposium, supra note 6.
68. See Kuzma et al., supra note 44.
69. Id.
70. See references to all case studies in this symposium, supra note 6.
71. National Research Council, Genetically Engineered Pest-Protected Plants: Science and Regulation (Washington, D.C. : National Academies Press, 2000).
72. See 21 C.F.R. 310.305; 21 C.F.R. 314.80 (2009).
73. See, e.g., 21 U.S.C. § 505(o)(4) regarding "new safety information" relevant to labeling. For a discussion of the impact of this provision, see S. D. Danzis and S. E. Pitlyk, "FDAAA's Safety Labeling Provisions," Food and Drug Law Institute Update Magazine, January/February 2009, at 10-13.
74. A. Wardak and M. Gorman, "Using Trading Zones and Life Cycle Analysis to Understand Nanotechnology Regulation Journal of Law, Medicine & Ethics 34, no. 4 (2006 695 703 Breggin and Pendergrass, supra note 28.
75. J. Wilsdon and R. Willis, "See-Through Science available at http://www.demos.co.uk last visited September 18, 2009); C. Toumey, "Science and Democracy," Nature Nanotechnology 1, no. 1 (2006): 6-7.
76. See Wardak and Gorman, supra note 56.
77. See Choi and Ramanchandran, supra note 6.
78. See Davies, Nanotechnology Oversight: An Agenda for the New Administration, supra note 28.
79. Food and Drug Administration Mission Statement, "What We Do available at http://www.fda.gov/opacom/morechoices/mission.html last visited September 18, 2009).